Advertisement
RVTY vs WAT
Which Stock Would AI Choose? Revvity (RVTY) vs. Waters (WAT) Stock Comparison
Key Takeaways
- WAT boasts superior profitability with a 20.3% profit margin and 29.28% return on equity (ROE, a measure of how effectively a company uses shareholders' equity to generate profits), compared to RVTY's 8.44% margin and 3.22% ROE.
- WAT has outperformed year-to-date with +19.14% returns versus RVTY's +10.28%, amid recent market volatility in life sciences tools.
- Both stocks trade at premiums but RVTY's trailing price-to-earnings (PE, stock price divided by earnings per share) ratio of 42.08 exceeds WAT's 28.54, signaling higher expectations for growth recovery.
- Quarterly revenue growth is comparable at 5.9% for RVTY and 6.8% for WAT, with upcoming Q1 2026 earnings likely to influence sentiment.
- Analyst price targets suggest ~26% upside for both: $109.73 for RVTY and $387 for WAT.
Introduction
Revvity (RVTY) and Waters (WAT) operate in the life sciences and diagnostics sector, providing essential instruments, software, and services for research and analysis. This comparison is relevant for investors seeking exposure to healthcare technology amid evolving market dynamics, including funding pressures and innovation demands. Traders monitoring relative performance may find value in their shared vulnerabilities to economic cycles and sector rotations, while differing financial profiles offer trade-offs in growth potential and stability.
RVTY Overview and Recent Performance
Revvity, Inc. delivers health sciences solutions, including reagents, instruments, and software for diagnostics and life sciences research. In recent market activity, RVTY shares approached their 52-week low near $81, reflecting concerns over revenue deceleration and margin compression amid softer funding environments. The stock's year-to-date gain of 10.28% has moderated, with a 1.86% monthly decline, influenced by mixed analyst views on growth sustainability. Positive catalysts include Q4 2025 earnings beats (EPS $1.70 vs. $1.58 expected) and 2026 guidance for 2-3% organic growth, bolstered by diagnostics strength and new AI-driven tools like Signals BioDesign. Shareholder actions, such as board re-elections and a dividend declaration, underscore ongoing stability efforts.
WAT Overview and Recent Performance
Waters Corporation specializes in analytical instruments and workflow solutions for pharmaceuticals, food safety, and materials science across Waters and TA segments. Recent weeks have seen WAT pull back from 52-week highs above $414, trading around $307 with a year-to-date rise of 19.14%, though quarterly dips reflect broader sector caution. Sentiment is buoyed by anticipation for Q1 2026 earnings on May 5, with expected EPS growth and revenue upticks, following Q4 beats. Robust margins and a history of earnings surprises support resilience, despite foreign exchange headwinds and competition. Recent insider activity and analyst optimism highlight potential for rebound in high-margin consumables demand.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 351 available, each deploying distinct strategies across stocks, ETFs, and crypto in sectors like semiconductors, data centers, and industrials. These bots deliver real-time signals with impressive stats: annualized returns ranging from +23.53% to +163.10%, win rates of 51.30% to 88.33%, and profit factors up to 11.70. Average trade durations span 1 day to 49 days, with profit-to-drawdown ratios as high as 17.02. Tailored for current volatility, they adapt via signal, virtual, and brokerage agents—no minimums for some. Explore these high-conviction options to enhance your trading edge in dynamic markets.
Head-to-Head Comparison
Both firms target life sciences instrumentation, but RVTY emphasizes diagnostics and software subscriptions, while WAT focuses on precision analytical tools with higher recurring consumables revenue. Growth drivers diverge: RVTY leverages AI innovations amid funding headwinds, versus WAT's margin strength from operational efficiency. Recent momentum favors WAT's YTD edge, though RVTY offers lower forward PE (16.05 vs. 21.37). Risks include RVTY's weaker ROE and higher debt leverage; WAT faces competition intensity. Sector exposure overlaps in healthcare, with sentiment tilting toward WAT's stability.
Tickeron AI Verdict
Tickeron’s AI currently leans toward WAT with higher probability, driven by superior margins, ROE, YTD momentum, and earnings consistency amid life sciences rotations. RVTY trails on recent stability but holds upside via guidance and valuation. Observable trends suggest WAT better positioned short-term, pending earnings catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVTY is a Hold and WAT is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 3 FA rating(s) are green whileWAT’s FA Score has 1 green FA rating(s).
- RVTY’s FA Score: 3 green, 2 red.
- WAT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 6 TA indicator(s) are bullish while WAT’s TA Score has 5 bullish TA indicator(s).
- RVTY’s TA Score: 6 bullish, 4 bearish.
- WAT’s TA Score: 5 bullish, 4 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а -5.91% price change this week, while WAT (@Medical Specialties) price change was -4.75% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.28%. For the same industry, the average monthly price growth was +13.41%, and the average quarterly price growth was -7.34%.
Reported Earning Dates
RVTY is expected to report earnings on Aug 03, 2026.
WAT is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical Specialties (-3.28% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| RVTY | WAT | RVTY / WAT | |
| Capitalization | 11B | 35.9B | 31% |
| EBITDA | 766M | 1.03B | 74% |
| Gain YTD | 1.816 | -3.810 | -48% |
| P/E Ratio | 47.29 | 46.48 | 102% |
| Revenue | 2.86B | 3.17B | 90% |
| Total Cash | N/A | 588M | - |
| Total Debt | 3.4B | 1.49B | 228% |
RVTY | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 82 | |
SMR RATING 1..100 | 89 | 34 | |
PRICE GROWTH RATING 1..100 | 28 | 45 | |
P/E GROWTH RATING 1..100 | 30 | 20 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RVTY's Valuation (14) in the Medical Specialties industry is somewhat better than the same rating for WAT (72). This means that RVTY’s stock grew somewhat faster than WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (82) in the Medical Specialties industry is in the same range as RVTY (100). This means that WAT’s stock grew similarly to RVTY’s over the last 12 months.
WAT's SMR Rating (34) in the Medical Specialties industry is somewhat better than the same rating for RVTY (89). This means that WAT’s stock grew somewhat faster than RVTY’s over the last 12 months.
RVTY's Price Growth Rating (28) in the Medical Specialties industry is in the same range as WAT (45). This means that RVTY’s stock grew similarly to WAT’s over the last 12 months.
WAT's P/E Growth Rating (20) in the Medical Specialties industry is in the same range as RVTY (30). This means that WAT’s stock grew similarly to RVTY’s over the last 12 months.
| RVTY | WAT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 57% |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 66% | 1 day ago 67% |
| MACD ODDS (%) | 1 day ago 71% | 1 day ago 60% |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 65% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 61% |
| Advances ODDS (%) | 2 days ago 66% | 8 days ago 64% |
| Declines ODDS (%) | 4 days ago 67% | 1 day ago 64% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 65% |
| Aroon ODDS (%) | 1 day ago 50% | 1 day ago 58% |
Advertisement